WebJun 16, 2024 · The recommended RETACRIT regimens are: 300 Units/kg per day subcutaneously for 15 days total: administered daily for 10 days before surgery, on the … WebEpoetin alfa is a human erythropoietin produced in cell culture using recombinant DNA technology. Authorised by the European Medicines Agency on 28 August 2007, it stimulates erythropoiesis (increasing red blood cell levels) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy.. Epoetin is …
RETACRIT Injection, Solution for Intravenous or Subcutaneous …
WebEpogen/Procrit based on extensive analytical characterization data, and demonstration that there are no clinically meaningful differences between “Epoetin Hospira” and US-licensed Epogen/Procrit based on clinical data on pharmacodynamics, pharmacokinetics, efficacy, safety, and immunogenicity. 2. Background WebRETACRIT $11.03‡ Procrit $25.72‡ $30.00 57% savings Potential Cost Savings With RETACRIT—Wholesale Acquisition Cost (WAC)† Represents a 57% Discount per 1000 Units vs Procrit3 * Biosimilars have no clinically meaningful differences from their reference product in terms of safety, purity, or potency.4 remington model 12 breech block
RATIONALE FOR INCLUSION IN PA PROGRAM
WebSafety Data in Support of Biosimilarity RETACRIT® (epoetin alfa-epbx) showed a similar safety profile to Epogen®/Procrit® (epoetin alfa) across adverse event (AE) categories 1-4. In comparative studies, RETACRIT showed comparable incidence of most common AEs. Frequency of common AEs (≥5%) across SC and IV studies In patients with CKD on … WebProcrit is used to treat anemia associated with kidney failure, HIV patients undergoing treatment, cancer patients undergoing therapy, and certain surgical patients. Reblozyl is an erythroid maturation agent and Procrit is a glycoprotein. Side effects of Reblozyl and Procrit that are similar include headache, bone pain, joint pain, fatigue ... WebRETACRIT demonstrated no clinically meaningful differences in efficacy compared to Epogen/Procrit 2 Studies in support of biosimilarity Review clinical data Loading RETACRIT showed a similar safety profile to Epogen/Procrit across adverse event categories 2-4 profile 2022 download